NCT07734597Not yet recruiting
Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?
Evaluation of Serum Irisin Levels as a Potential Biomarker in Patients With Diabetic Polyneuropathy: A Single-center Prospective Cross-sectional Observational Study
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 81 (estimated)
- First submitted
- 6 Jul 2026
- Start date
- 30 Jul 2026
- Primary completion date
- 30 Jul 2026
- Lead sponsor
- GÜLDEN ANATACA
- Diseases
- Type 2 diabetes
- NCT number
- NCT07734597
What you commit to
- Study type: Observational
- Planned participants: 81
- From 30 Jul 2026 to the primary completion date, 30 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chronic alcohol use, chemotherapy-induced neuropathy)
- Active infection
- Myopathies or other muscle diseases
- Central nervous system diseases (e.g., stroke, Parkinson disease)
- Severe orthopedic conditions impairing mobility
Lab values
- Chronic kidney disease (eGFR \<60 mL/min/1.73 m²)
Other
- Inability or unwillingness to provide informed consent
Who the study is looking for
- Age between 30 and 75 years
- Diagnosis of Type 2 Diabetes Mellitus for at least 1 year (for diabetic groups)
- Ability to understand and sign informed consent
- Willingness to participate in the study
Age in the registry: 30 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kanuni Sultan Süleyman Training and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.